BTTX (BTTX) Stock Price & Analysis
BTTX (BTTX) rose 0.00% to USD 0 as of June 10, 2026 at 03:33 UTC, according to Nexqual real-time market data.
BTTX last closed at USD 0; the session ranged USD 0–0 on volume of 500 shares. Market capitalization is $5,451, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:33 UTC.
Key Statistics (as of June 10, 2026 at 03:33 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 500 shares |
| Market Cap | $5,451 |
| Exchange | PNK |
Technical Analysis (BTTX)
Nexqual's technical model rates BTTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:33 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (BTTX)
Wall Street analysts rate BTTX "None", per Nexqual as of June 10, 2026 at 03:33 UTC.
| Consensus Rating | None |
|---|
Earnings (BTTX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.15 vs est -0.2 ▲ beat |
| 2023-06-30 | USD -0.24 vs est -0.31 ▲ beat |
| 2023-03-31 | USD -0.39 vs est -0.31 ▼ miss |
| 2022-12-31 | USD -0.37 vs est -0.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Financials & Fundamentals (BTTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.57 |
| Total Cash | $6.60M |
| Total Debt | $14.31M |
| Free Cash Flow | $-15.56M |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Financial Health Score (BTTX)
Nexqual rates BTTX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $7M cash vs $14M debt |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Mixed — No data |
Ownership (BTTX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 54.52M |
| Float | 30.54M |
| Short % of Float | +6.21% |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Leadership (BTTX)
BTTX is led by David P. Perry (age 57), Co-Founder & Executive Chairman, per Nexqual as of June 10, 2026 at 03:33 UTC.
| Co-Founder & Executive Chairman | David P. Perry (age 57) |
|---|---|
| Interim CFO | Frank L. Karbe (age 57) |
| Chief Product Officer | Kristin Wynholds (age 52) |
| Senior Vice President of Market Access | Angela Willis |
Major Backers & Investors (BTTX)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.4% |
Source: Nexqual, June 10, 2026 at 03:33 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 8.33% |
| EFTR | eFFECTOR Therapeutics, Inc. | USD 0 | ▲ 0% |
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.76 | ▲ 1.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:33 UTC. This page is informational and not investment advice.